These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Strain-specificity of antibody to haemagglutinin following inactivated A/port chalmers/1/73 vaccine in man: evidence for a paradoxical strain-specific antibody response.
    Author: Schild GC, Smith JW, Cretescu L, Newman RW, Wood JM.
    Journal: Dev Biol Stand; ; 39():273-81. PubMed ID: 604109.
    Abstract:
    An analysis was carried out of the anti-haemagglutinin antibody responses in adult human recipients of inactivated whole virus A/Port Chalmers/1/73 (H3N2) vaccine using single radial diffusion combined with antibody adsorption techniques to determine antibody specificity. Antibody was characterised as cross-reactive (i.e. directed against antigenic determinants of haemagglutinin which are common for viruses within the H3 subtype) or strain-specific. Strain-specific antibodies for the vaccine strain and also for A/Hong Kong/68(H3N2) virus were assayed. A high proportion of vaccinees developed antibody of the cross-reactive specificity. The titre and frequency of such antibody increased with vaccine dose (100 iu to 1600 iu per dose). Many individuals developed strain-specific in addition to cross-reactive antibodies. A notable finding was that in 70% of vaccinees who developed strain-specific antibody, this was a paradoxical response directed against the strain specific determinant of A/Hong Kong/68 virus (the first number of the H3 subtype). Only 30% developed strain-specific antibody to the haemagglutinin of the vaccine strain. The percentage of vaccinees developing strain-specific antibodies to the vaccine strain was not significantly increased by increasing the dose of vaccine to 1600 iu. A second dose of A/Port Chalmers/73 vaccine administered approximately one year after the first dose only slightly increased the percentage with A/Port Chalmers strain-specific antibody.
    [Abstract] [Full Text] [Related] [New Search]